188th ENMC international workshop: Inclusion body myositis, 2-4 December 2011, Naarden, the Netherlands

Neuromuscular Disorders

Volumn 23, Issue 12, 2013, Pages 1044-1055

  Rose, M R ^a   Amato, Anthony A ^b   van Engelen, Baziel ^c   Tseng, Brian ^d   Buccirechtweg, Christina ^d   Jones, David Hilton ^e   Seedat, Farah ^f   Lundberg, Ingrid E ^g   Miller, James ^h   De Bleecker, Jan ⁱ   Schmidt, Jens ^j   Vissing, John ^k   Lowes, Linda ^l   Dewar, Liz ^m   Walter, Maggie C ⁿ   de Visser, Marianne ^o   Taylor, Martin ^r   Needham, Merrilee ^p   Hanna, Michael ^m   Rose, Michael ^f   Benveniste, Olivier ^q   Leff, Richard ^r   Sejersen, Thomas ^g   Hindle, Tony ^s   Badrising, Umesh ^t   Tawil, Rabi ^u   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Neuromuscular Centre Nijmegen   (Netherlands)

^d NOVARTIS PHARMA AG   (Switzerland)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h ROYAL VICTORIA INFIRMARY   (United Kingdom)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j University Medical Centre   (Germany)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l NATIONWIDE CHILDREN S HOSPITAL   (United States)

^m NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o ACADEMIC MEDICAL CENTER   (Netherlands)

^p Molecular Genetic Therapy Group   (Australia)

^q Centre de Référence Neuromusculaire   (France)

^r Myositis Support Group ^*

^s Myositis Support Group   (United Kingdom)

^t LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^u UNIVERSITY OF ROCHESTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AZATHIOPRINE; GAMMA INTERFERON; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; PREDNISOLONE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE REGISTRY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DUCHENNE MUSCULAR DYSTROPHY; ELECTROMYOGRAPHY; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; INCLUSION BODY MYOSITIS; INTERNATIONAL COOPERATION; LABORATORY TEST; MEDICAL EDUCATION; MUSCLE BIOPSY; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; STANDARD; WORKSHOP;

CLINICAL TRIALS AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; MYOSITIS, INCLUSION BODY; NETHERLANDS;

EID: 84888431952     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.08.007     Document Type: Article

References (70)

1. Benveniste O., Hilton-Jones D. International workshop on inclusion body myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 2010, 20:414-421.
2. Hilton-Jones D., Miller A., Parton M., Holton J., Sewry C., Hanna M.G. Inclusion body myositis: MRC centre for neuromuscular diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010, 20:142-147.
3. Griggs R.C., Askanas V., DiMauro S., Engel A.G., Kapati G., Mendell J.R., et al. Inclusion body myositis and myopathies. Annal Neurol 1995, 38:705-713.
4. Chahin N., Engel A.G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008, 70:418-424.
5. Verschuuren U.A., Wintzen A.R., van Engelen B.G., van der Hoeven H., Hoogendijk J. Inclusion body myositis. Diagnostic criteria for neuromuscular disorders 1997, 81-84. Royal Society of Medicine, ENMC, London. A. E. H. Emery (Ed.).
6. Meyer H., Bug M., Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol 2012, 14:117-123.
7. Benjamin Larman H, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408-18.
8. Pluk H., van Hoeve B.J., van Dooren S.H., Stammen-Vogelzangs J., van der Heijden A., Schelhaas H.J., et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013, 73:397-407.
9. Schmidt J.B.K., Wrede A., Salajegheh M., Bähr M., Dalakas M.C. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228-1240.
10. Kitazawa M.T.D., LaFerla F.M. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008, 64:15-24.
11. Muth I.E.B.K., Bähr M., et al. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of aB-crystallin is associated with amyloid precursor protein and accumulation of bamyloid. J Neurol Neurosurg Psychiatry 2009, 80:1344-1349.
12. Keller C.W., Fokken C., Turville S.G., Lünemann A., Schmidt J., Münz C., et al. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J Biol Chem 2011, 286:3970-3980.
13. Schmidt J. Of amyloid and inflammation: causes of chronic muscle disease. e-Neuroforum 2010, 1:81-88.
14. Needham M., Corbett A., Day T., Christiansen F., Fabian V., Mastaglia F.L. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008, 15:1350-1353.
15. Serdaroglu P., Deymeer F., Parman Y. Prevalence of sporadic inclusion body myositis (s-IBM) in Turkey: a muscle biopsy-based survey. Neuromuscul Disord 2007, 17:849.
16. Scott A.P., Laing N.G., Mastaglia F., Needham M., Walter M.C., Dalakas M.C., et al. Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex. J Neuroimmunol 2011, 235:77-83.
17. Mastaglia F.L., Needham M., Scott A., James I., Ziko P., Day T., et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord 2009, 19:763-765.
18. Sivakumar K., Cervenakova L., Dalakas M.C., Leon-Monzon M., Isaacson S.H., Nagle J.W., et al. Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Ann Neurol 1995, 38:267-269.
19. Orth M., Tabrizi S.J., Schapira A.H. Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology 2000, 55:1235.
20. Salajegheh M., Pinkus J.L., Taylor P.J., Amato A.A., Nazareno R., Baloh R.H., et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle & Nerve 2009, 40:19-31.
21. Gossrau G., Gestrich B., Koch R., Wunderlich C., Schroder J.M., Schroeder S., et al. Apolipoprotein E and alpha-1-antichymotrypsin polymorphisms in sporadic inclusion body myositis. Eur Neurol 2004, 51:215-220.
22. Needham M., Hooper A., James I., van Bockxmeer F., Corbett A., Day T., et al. Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal. Neuromuscul Disord 2008, 18:150-152.
23. Askanas V., Engel W.K., Mirabella M., Weisgraber K.H., Saunders A.M., Roses A.D., et al. Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Ann Neurol 1996, 40:264-265.
24. Harrington C.R., Anderson J.R., Chan K.K. Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis. Neurosci Lett 1995, 183:35-38.
25. Love S., Nicoll J.A., Lowe J., Sherriff F. Apolipoprotein E allele frequencies in sporadic inclusion body myositis. Muscle & Nerve 1996, 19:1605-1607.
26. Vasconcelos O.M., Raju R., Dalakas M. GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM. Neurology 2002, 59:1776-1779.
27. Machado P., Hudson J., Miller A., Morrow J., Parton M., Bushby K., et al. Valosin containing protein (VCP) and myofibrillar myopathies (MFM) genes' mutations are not associated with sporadic inclusion body myositis (sIBM). JNNP 2012, 83:3e1.
28. Ranque-Francois B., Maisonobe T., Dion E., Piette J.C., Chauveheid M.P., Amoura Z., et al. Familial inflammatory inclusion body myositis. AnnRheumDis. 2005, 64:634-637.
29. Amato A.A., Shebert R.T. Inclusion body myositis in twins. Neurology 1998, 51:598-600.
30. Naumann M., Toyka K.V., Amato A.A., Shebert R.T. Inclusion body myositis in twins; correspondence. Neurology 1999, 53:656.
31. Sivakumar K., Semino-Mora C., Dalakas M.C. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families. Brain 1997, 120:653-661.
32. Griggs R.C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J.R., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
33. Lotz B.P., Engel A.G., Nishino H., Stevens J.C., Litchy W.J. Inclusion body myositis. Observations in 40 patients. Brain 1989, 112(Pt. 3):727-747.
34. Lindberg C., Persson L.I., Bjorkander J., Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994, 89:123-131.
35. Amato A.A., Gronseth G.S., Jackson C.E., Wolfe G.I., Katz J.S., Bryan W.W., et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996, 40:581-586.
36. Badrising U.A., Maat-Schieman M.L., van Houwelingen J.C., van Doorn P.A., van Duinen S.G., van Engelen B.G., et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol 2005, 252:1448-1454.
37. Felice K.J., North W.A. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine (Baltimore) 2001, 80:320-327.
38. Cox F.M., Titulaer M.J., Sont J.K., Wintzen A.R., Verschuuren J.J., Badrising U.A. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011, 134:3167-3175.
39. Rose M.R., McDermott M.P., Thornton C.A., Palenski C., Martens W.B., Griggs R.C. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001, 57:548-550.
40. Dalakas M.C., Rakocevic G., Schmidt J., Salajegheh M., McElroy B., Harris-Love M.O., et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009, 132:1536-1544.
41. Crosby C.A., Wehbe M.A., Mawr B. Hand strength: normative values. J Hand Surg Am 1994, 19:665-670.
42. Tawil R., Griggs R.C. Inclusion body myositis. Curr Opin Rheumatol 2002, 14:653-657.
43. Hayter S.M., Cook M.C. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012.
44. Needham M., Mastaglia F.L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007, 6:620-631.
45. Benveniste O., Guiguet M., Freebody J., Dubourg O., Squier W., Maisonobe T., et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011, 134:3176-3184.
46. Peng A., Koffman B.M., Malley J.D., Dalakas M.C. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000, 55:296-298.
47. Rose MR, Griggs R, Dalakas M. Immunotherapy for inclusion body myositis (Protocol for a Cochrane Review). Issue 4 ed: Update software; 1999.
48. Barohn R.J., Amato A.A., Sahenk Z., Kissel J.T., Mendell J.R. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995, 45:1302-1304.
49. Dalakas M.C., Koffman B., Fujii M., Spector S., Sivakumar K., Cupler E. A controlled study of intravenous immunoglobulin combined with prednisolone in the treatment of IBM. Neurology 2001, 56:323-327.
50. Muscle Study Group. Randomized pilot trial of INF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57:1566-70.
51. Skalsky A.J., Abresch R.T., Han J.J., Shin C.S., McDonald C.M. The relationship between regional body composition and quantitative strength in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2008, 18:873-880.
52. Skalsky A.J., Han J.J., Abresch R.T., Shin C.S., McDonald C.M. Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength. Muscle & Nerve 2009, 39:647-651.
53. Vanhoutte E.K., Faber C.G., van Nes S.I., Jacobs B.C., van Doorn P.A., van Koningsveld R., et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 2011.
54. Lowes L.P., Alfano L., Viollet L., Rosales X.Q., Sahenk Z., Kaspar B.K., et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle & Nerve 2012, 45:163-168.
55. Allenbach Y., Benveniste O., Decostre V., Canal A., Eymard B., Herson S., et al. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord 2012, 22:980-986.
56. Jackson C.E., Barohn R.J., Gronseth G., Pandya S., Herbelin L. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle & Nerve 2008, 37:473-476.
57. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63:718-20.
58. Benveniste O., Guiguet M., Freebody J., Dubourg O., Squier W., Maisonobe T., et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011, 134:3176-3184.
59. Sadjadi R., Rose M.R. What determines quality of life in inclusion body myositis?. J Neurol Neurosurg Psychiatry 2010, 81:1164-1166.
60. Vincent K.A., Carr A.J., Walburn J., Scott D.L., Rose M.R. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007, 68:1051-1057.
61. Badrising U.A., Maat-Schieman M., van Duinen S.G., Breedveld F., van Doorn P., van Engelen B., et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000, 55:1385-1388.
62. Eccles M., Clapp Z., Grimshaw J., Adams P.C., Higgins B., Purves I., et al. North of England evidence based guidelines development project: methods of guideline development. BMJ 1996, 312:760-762.
63. Eccles M., Clapp Z., Grimshaw J., Adams P.C., Higgins B., Purves I., et al. Developing valid guidelines: methodological and procedural issues from the North of England evidence based guideline development project. Qual Health Care 1996, 5:44-50.
64. AAN, Clinical practice guideline process manual. In:neurology TAAo, editor. 2011, American Academy of Neurology: St. Paul, MN, USA.
65. CMA. Guidelines for canadian clinican practice guidelines. Canadian Medical Association; 1993.
66. SIGN. SIGN 50 handbook. Scottish Intercollegiate Guidelines Network; 2011 cited; Available from: . http://www.sign.ac.uk/guidelines/fulltext/50/index.html.
67. Dalakas M.C., Sonies B., Dambrosia J., Sekul E., Cupler E., Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997, 48:712-716.
68. Walter M.C., Lochmuller H., Toepfer M., Schotter B., Reilich P., Schroder M., et al. High dose immunglobulin therapy in sporadic inclusion body myositis: a double blind, placebo-controlled study. J Neurol. 2000, 247:22-28.
69. Rutkove S.B., Parker R.A., Nardin R.A., Connolly C.E., Felice K.J., Raynor E.M. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002, 58:1081-1087.
70. Badrising U.A., Maat-Schieman M.L., Ferrari M.D., Zwinderman A.H., Wessels J.A., Breedveld F.C., et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Annal Neurol. 2002, 51:369-372.